Delcath sells $20m in stock at three-year-low price to advance hepatic chemo system
This article was originally published in Scrip
Executive Summary
Ahead of its new drug application (NDA) filing with the US FDA at the end of the summer, Delcath Systems plundered $20 million on 25 May from the public markets with a bottom-trawling stock offering at the company's lowest stock price in the past three years. The money has been raised to commercialise its Chemosat chemotherapy drug delivery system.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.